[Immunotherapy: Activation of a system not a pathway]

Emilie Bernichon; Chloé Rancoule; Alexis Vallard; Julien Langrand-Escure; Benoîte Mery; Jean-Baptiste Guy; Nicolas Magné

doi:10.1016/j.bulcan.2017.03.004

[Immunotherapy: Activation of a system not a pathway]

Bull Cancer. 2017 May;104(5):462-475. doi: 10.1016/j.bulcan.2017.03.004. Epub 2017 May 3.

[Article in French]

Authors

Emilie Bernichon¹, Chloé Rancoule², Alexis Vallard³, Julien Langrand-Escure³, Benoîte Mery⁴, Jean-Baptiste Guy², Nicolas Magné⁵

Affiliations

¹ Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France.
² Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; CNRS UMR 5822, laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France.
³ Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France.
⁴ Institut de cancérologie Lucien-Neuwirth, département d'oncologie médicale, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; CNRS UMR 5822, laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France.
⁵ Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France; CNRS UMR 5822, laboratoire de radiobiologie cellulaire et moléculaire de Lyon Sud, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France. Electronic address: nicolas.magne@icloire.fr.

PMID: 28477871
DOI: 10.1016/j.bulcan.2017.03.004

Abstract

Immunotherapy is on the roll. After revolutionary effects in melanoma, immunotherapy is invading other locations. If current treatments, chemotherapies or targeted therapies block one pathway, immunotherapy should be understood as the activation of a whole system. Indeed, oncogenesis process is defined as an escape of the immune system and the stimulation of this system can block the carcinogenic process. The aim of the present review is to describe the place of immunotherapy in the treatment of solid cancers.

Keywords: Immunotherapy; Immunothérapie; Lungs; Melanoma; Mélanomes; Oncogenesis; Oncogenèse; Poumons; Reins; Waist.

Publication types

Historical Article
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Cancer Vaccines / therapeutic use
Female
Gastrointestinal Neoplasms / therapy
Genital Neoplasms, Female / therapy
History, 19th Century
History, 20th Century
History, 21st Century
Humans
Immunity, Cellular
Immunotherapy / history
Immunotherapy / methods*
Ipilimumab
Kidney Neoplasms / therapy
Lung Neoplasms / therapy
Melanoma / immunology
Melanoma / therapy
Neoplasms / immunology
Neoplasms / pathology
Neoplasms / therapy*
Nivolumab
Otorhinolaryngologic Neoplasms / therapy
Tumor Escape / immunology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cancer Vaccines
Ipilimumab
Nivolumab
atezolizumab
pembrolizumab